NovelDx in the News
CARB-X Funding Announcement
April 6th, 2021, 7:00 AM ET Novel Microdevices, Inc. awarded up to $13.8 million from CARB-X for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections (Baltimore, Maryland) - Novel Microdevices, Inc.,(Novel) a developer of an innovative molecular diagnostics platform, announced today that CARB-X has awarded it up to $13.8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections,...
The Baltimore Sun’s 25 Women to Watch 2021: Best in advocacy, business and health (Baltimore Sun staff)
The Baltimore Sun’s 25 Women to Watch 2021: Best in advocacy, business and health (Baltimore Sun staff) Andrea Pais is the co-founder and CEO of Novel Microdevices, a developer of diagnostic testing systems. (PHOTO by Lloyd Fox/Baltimore Sun) Growing up in South India, Andrea Pais saw firsthand the need for portable, rapid testing for all sorts of illnesses — especially in remote areas of the country, which she said sometimes are days away from the nearest hospital. It drove the 37-year-old Baltimore-based entrepreneur to co-found Novel Microdevices in 2015 and begin developing a testing...
Carb-X announces up to $13.8m funding for STIs diagnostic
Novel Microdevices, Inc. awarded up to $13.8 million from CARB-X for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections
CARB-X Funding Announcement
April 6th, 2021, 7:00 AM ET Novel Microdevices, Inc. awarded up to $13.8 million from CARB-X for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections (Baltimore, Maryland) - Novel Microdevices, Inc.,(Novel) a developer of an innovative molecular diagnostics platform, announced today that CARB-X has awarded it up to $13.8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections,...